KLDO — Kaleido Biosciences Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$16.78m
- $1.10m
NASDAQ RESUMED AT 10:14 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:10 AM
NASDAQ RESUMED AT 10:09 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:04 AM
NASDAQ RESUMED AT 10:03 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:59 AM
NASDAQ RESUMED AT 09:56 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 09:20 AM
Kaleido Biosciences Inc expected to post a loss of 58 cents a share - Earnings Preview
Brief: Kaleido Biosciences To Halt Work On Planned Phase 2 Chronic Obstructive Pulmonary Disease Study, Terminate Agreement With COPD Foundation
Brief: Kaleido Biosciences To Present Updated Data Of Kb295 In Ulcerative Colitis At The 2022 Crohn’S And Colitis Congress
Brief: Kaleido Biosciences Announces Expansion Of Collaboration With Janssen To Explore Potential Of Microbiome Metabolic Therapies (Mmt) To Prevent Childhood-Onset Of Atopic, Immune And Metabolic Conditions
Brief: Kaleido Biosciences To Appoint Alison Long As Chief Medical Officer
Kaleido Biosciences Inc reports results for the quarter ended in September - Earnings Summary
Brief: Kaleido Biosciences Reports Third Quarter 2021 Financial Results
Kaleido Biosciences Inc expected to post a loss of 54 cents a share - Earnings Preview
Kaleido slumps after stopping clinical trial
Brief: Kaleido Biosciences Inc Announces New Clinical And Preclinical Data Supporting Advancement Of KB295 To A Phase 2 Clinical Study In Mild-To-Moderate Ulcerative Colitis
Brief: Kaleido Biosciences Received Warning Letter From U.S. FDA